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appropriateness of including our trial in the same 
group as the other randomized glutamine trials 
performed in the critical care setting, given dif-
ferences in patient population, administration 
route, dosage, and approach to feeding.
Buijs et al. express several concerns that we 
believe are overstated. First, we attempted to 
optimize nutrition delivery through the applica-
tion of evidence-informed strategies. Our suc-
cess with feeding is probably consistent with the 
results in most intensive care units worldwide. 
The overall degree of imbalance in baseline 
characteristics is consistent with expected ran-
dom variation and did not affect our conclu-
sions. Our prespecified analysis plan, which 
followed best practices for factorial, random-
ized, controlled trials, did not adjust for the 
number of organ failures.2-5 Nevertheless, when 
we adjust for important baseline characteristics 
(including organ failures), the adjusted odds ra-
tio of 28-day mortality for glutamine as com-
pared with placebo remains consistent with our 
primary analysis, at 1.4 (95% confidence inter-
val, 1.0 to 2.1; P = 0.05). Finally, our secondary 
6-month mortality results were based on sur-
vival analysis techniques that remain valid in the 
presence of random loss to follow-up. Besides, 
almost the entire treatment effect was observed 
within the first 30 days, when there was almost 
no loss to follow-up.
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Weight Loss in Persons with Serious Mental Illness
To the Editor: Daumit and colleagues (April 25 
issue)1 describe the results of the Randomized 
Trial of Achieving Healthy Lifestyles in Psychiat-
ric Rehabilitation (ACHIEVE), and they report 
that an intensive behavioral weight-loss interven-
tion significantly reduced weight in adults with 
severe mental illness. This comprehensive inter-
vention used existing rehabilitation-program staff 
in community-based psychiatric rehabilitation 
settings.
Unfortunately, the 2011 Centers for Medicare 
and Medicaid Services (CMS) policy for weight-
loss counseling2 would not cover this effective 
intervention. The CMS policy covers only brief 
weight-loss counseling delivered by primary care 
physicians in primary care settings, not the com-
prehensive counseling by behavioral providers in a 
rehabilitation setting that Daumit and colleagues 
found effective. Current CMS policy will have 
little effect on health disparities because popula-
tions that are disproportionately affected by obe-
sity often use the services of community-based 
organizations. Further, unlike the offices of most 
primary care doctors, community clinics employ 
behavioral counselors and typically have facilities 
(e.g., kitchens and recreation rooms) that are con-
ducive to behavioral weight-loss programs.
The study by Daumit et al. and other commu-
nity-based obesity trials3 provide support for the 
case for CMS to cover a wider range of settings 
and providers. This is not only consistent with 
the evidence but is also the most feasible ap-
proach to reducing weight in underserved popu-
lations.
The New England Journal of Medicine 
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To the Editor: Daumit et al. bring to light an 
important and often overlooked dynamic of 
treating patients with mental illness. Since one 
third of the U.S. population is classified as obese, 
and mentally ill patients are at increased risk for 
being overweight, it is critical that all health care 
professionals, specifically those working within 
the mental health field, integrate within the pa-
tient–physician relationship a discussion regard-
ing healthy eating and lifestyle habits.
As mental health care providers struggle to 
do more with less funding, this study exempli-
fies what can be accomplished with relatively 
low overhead. The seamless integration of the 
ACHIEVE protocol into outpatient mental health 
centers and the use of the already established 
infrastructure within these centers increase the 
validity of this study.
Future studies of the effect of this behavioral 
intervention on coexisting conditions such as 
cardiovascular disease, diabetes, and dyslipid-
emia may reinforce the importance of addressing 
the benefits of a healthy lifestyle with patients 
who have mental illness.
Joshua R. Ackerman, M.D.
New York Medical College 
New York, NY
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The Authors Reply: The implementation and 
dissemination of effective lifestyle interventions 
are critical to stem the epidemic of obesity and 
obesity-related conditions in persons with seri-
ous mental illness. However, incorporating 
weight-loss interventions into behavioral health 
settings will require financial and organizational 
resources that are unavailable in most commu-
nity mental health settings. Community mental 
health programs are often under financial stress, 
and mental health, not physical health, is their 
first priority.
As Pagoto et al. state, the current CMS policy 
of providing reimbursement for weight counsel-
ing by primary care physicians would not be 
applicable to the ACHIEVE intervention, which 
was delivered by health coaches and staff. How-
ever, the federal government does provide two 
potential sources of funding for health promo-
tion to organizations that serve persons with 
serious mental illness. The Patient Protection 
and Affordable Care Act (ACA) “health home” 
provision gives states additional federal funding 
for care management and the use of clinical in-
formation systems by Medicaid providers to en-
hance coordination of medical and behavioral 
health care.1 Eligible Medicaid recipients must 
have a serious and persistent mental health con-
dition, two or more chronic mental or physical 
health conditions, or one mental or physical 
condition with a high risk of another. Primarily 
through ACA funding, the Substance Abuse and 
Mental Health Services Administration has 
awarded more than 60 grants to community-
based agencies with the goal of building infra-
structure to support integration of primary care 
services for persons with serious mental illness.2 
These initiatives do not explicitly fund lifestyle 
interventions, although program resources could 
be used for incorporating health promotion into 
mental health care. Still, these two initiatives 
are modest in scope. We concur with Pagoto and 
colleagues that broader coverage of weight-
management counseling is needed.
We also agree with Ackerman that incorpo-
rating healthy-lifestyle interventions into com-
munity mental health programs, particularly 
those such as psychiatric rehabilitation pro-
grams that mental health consumers attend 
frequently, is a wonderful but unrealized oppor-
tunity to leverage the existing infrastructure. 
The New England Journal of Medicine 
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Weight-loss interventions could be incorporated 
into regular programming. In any case, imple-
menting the ACHIEVE intervention into a broad-
er array of community mental health settings 
would require resources to ensure the effective 
translation of our findings into practice.
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Darbepoetin Alfa in Systolic Heart Failure
To the Editor: In their report on the Reduction 
of Events by Darbepoetin Alfa in Heart Failure 
 (RED-HF) trial, Swedberg et al. (March 28 issue)1 
conclude that the correction of anemia with the 
use of darbepoetin alfa in patients with heart fail-
ure does not reduce the rate of cardiovascular end 
points. This finding is in line with the results of 
the Trial to Reduce Cardiovascular Events with 
Aranesp Therapy (TREAT).2 However, it may be 
difficult to generalize such results to all forms of 
anemia in heart failure, especially to anemia 
caused by iron deficiency. As found by Toblli et al.3 
and also shown in the Ferinject Assessment in Pa-
tients with Iron Deficiency and Chronic Heart 
Failure (FAIR-HF) trial,4 iron supplementation in 
patients with heart failure and iron deficiency 
reduces N-terminal pro–brain natriuretic peptide 
levels and improves symptoms and functional ca-
pacity. Since the FAIR-HF trial did not evaluate ob-
jective end points, the follow-up Iron in Congestive 
Heart Failure (ICHF) trial (ClinicalTrials.gov num-
ber, NCT01837082) will evaluate the effect of iron 
supplementation on left ventricular ejection frac-
tion and renal  function with the use of magnetic 
resonance imaging of the heart and radionucleo-
tide  measurement.
It seems plausible to assume that taking into 
account the patient’s iron status in the therapeu-
tic regimen may be superior to an approach fo-
cusing only on the hemoglobin level. Therefore, 
it is important that the authors stratify the pri-
mary end point according to the iron status at 
baseline, especially since iron deficiency was 
rigorously corrected during the trial.
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To the Editor: The RED-HF investigators found 
that darbepoetin alfa had no effect in patients 
with anemia and heart failure. But was the un-
treated group really untreated? Almost all the 
patients came into the program with a normal 
transferrin saturation of more than 20%; indeed, 
the median level was 24% (interquartile range, 
19 to 31). This percentage is much above what is 
typically found in heart failure, in which the ma-
jority of patients have a transferrin saturation of 
less than 20%, suggesting iron deficiency.1-3 
Thus, presumably the iron deficiency was cor-
rected before they entered the study. In addition, 
once enrolled in the program, the great majority 
of patients received intravenous iron, oral iron, 
The New England Journal of Medicine 
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